Fox Chase Cancer Center News

PHILADELPHIA (October 6, 2020) – Researchers at Fox Chase Cancer Center have discovered a new function for the histone lysine demethylase KDM4A that supports its role as a “critical regulator” for replicative histones during the S phase of the cell cycle.

PHILADELPHIA (October 6, 2020)—In a recent study, researchers at Fox Chase Cancer Center found individuals with lower health literacy or income reported more practical issues and problems with coping following localized prostate cancer treatment.

PHILADELPHIA (October 1, 2020) – Active surveillance is being increasingly used as a treatment option for men diagnosed with low-risk prostate cancer. A recent study led by researchers at Fox Chase Cancer Center, however, has found that only about 60% of men who choose active surveillance are undergoing guideline-recommended confirmatory biopsy within 12 months of their diagnosis.

PHILADELPHIA (September 30, 2020)—Researchers at Fox Chase Cancer Center were recently awarded a grant through the National Institute of Dental and Craniofacial Research to fund a Specialized Program of Research Excellence (SPORE) for Head and Neck Cancer.

PHILADELPHIA (October 1, 2020)—Researchers at Fox Chase Cancer Center recently published a commentary examining clinical practices for breast cancer detection using traditional mammography versus digital breast tomosynthesis on baseline and subsequent screenings.

PHILADELPHIA (September 28, 2020)—In a recent study, researchers at Fox Chase Cancer Center found that more women with breast cancer seek help with sexual problems from partners or family than their healthcare providers.

PHILADELPHIA (September 28, 2020)—In a study published today in the prestigious journal Cancer Cell, researchers at Fox Chase Cancer Center showed how altering lipid metabolism may contribute to sustaining tumor growth in patients with pancreatic ductal adenocarcinoma. The finding could help overcome a major problem in pancreatic cancer treatment resistance and metastatic spread, the researchers said.

PHILADELPHIA (September 24, 2020)—Researchers at Fox Chase Cancer Center recently published the results of an international study showing improved survival for patients with advanced gastrointestinal stromal tumors who used ripretinib (Qinlock) when compared with patients taking a placebo.